The Galleri Multi-Cancer Blood Test: Is $950/Year Worth It?

The Bottom Line

The Galleri test is a blood draw that screens for 50+ cancer types by detecting cancer-derived DNA methylation patterns. In the PATHFINDER 2 trial (25,578 participants, 2025), adding Galleri to standard screening increased cancer detection more than 7-fold. The NHS-Galleri trial showed a 4-fold higher detection rate with substantial reduction in Stage IV diagnoses. Early detection is where survival outcomes are determined: Stage I vs. Stage IV is often the difference between 95% and 10-15% five-year survival. This may be the single highest-leverage intervention available for cancer prevention.

How It Works

Cancer cells shed fragments of their DNA into the bloodstream (cell-free DNA, or cfDNA). Galleri detects these fragments using a technique called targeted methylation sequencing. Methylation patterns are like molecular fingerprints: they differ between cancer types and normal tissue.

The test doesn't just detect whether cancer is present. It also predicts the cancer signal origin, telling you where in the body the cancer likely is. This dramatically reduces the diagnostic workup needed after a positive result.

The Trial Data

PATHFINDER 2 (October 2025)

25,578 participants, 12-month follow-up
Galleri added to standard screening increased cancer detection more than 7-fold
Large fraction of cancers detected at Stage I or II, before symptoms appeared
Cancer signal origin prediction was accurate in the majority of cases, reducing unnecessary invasive workups

NHS-Galleri Trial (UK)

Largest multi-cancer screening trial ever conducted
4-fold higher cancer detection rate in the Galleri arm
Substantial reduction in Stage IV diagnoses (late-stage cancers caught earlier)
This trial is being used to inform potential NHS-wide rollout in the UK

What It Detects (and Doesn't)

Galleri screens for over 50 cancer types, including many that have no existing screening test:

Pancreatic, ovarian, liver, bile duct, stomach cancers (currently detected late, often fatal)
Esophageal, head and neck, kidney, bladder cancers
Lymphoma, leukemia, multiple myeloma
Plus standard cancers: lung, breast, colorectal, prostate

Limitations: Galleri is designed as a complement to, not a replacement for, existing screening (mammograms, colonoscopies, PSA). Its sensitivity is highest for late-stage cancers and lower for Stage I. It can miss cancers. A negative result does not mean you're cancer-free. It's an additional layer of detection.

False Positives and False Negatives

In PATHFINDER, the false positive rate was very low (<1%). This matters because cancer screening tests that produce high false positive rates lead to unnecessary biopsies, anxiety, and medical costs. Galleri's specificity (>99%) is one of its strongest features.

False negatives are more common, especially for early-stage cancers. Galleri catches a meaningful percentage of cancers that would otherwise be missed, but it doesn't catch all of them. Think of it as a net that catches many fish but lets some small ones through.

Cost and Availability

Price: ~$949 per test (2026 pricing). Recommended annually.
Insurance: Not covered by most insurance plans (not yet FDA-approved as a screening test)
Availability: Available through participating healthcare providers in the US as a laboratory-developed test
FDA status: Not yet FDA-approved for general screening. Breakthrough Device designation granted. Likely FDA pathway within 1-2 years based on trial results.

Who Should Consider It

Anyone over 50 (cancer risk increases significantly with age)
Those with family history of cancer, especially cancers with no standard screening
Anyone who can afford $950/year and wants maximum early detection coverage
People with cancer risk factors (smoking history, obesity, genetic predispositions)

The AI Behind It

Galleri uses machine learning classifiers trained on methylation patterns from hundreds of thousands of samples. The AI doesn't just look for "cancer or not cancer." It's been trained to recognize tissue-of-origin methylation signatures, which is why it can tell you not just that cancer is detected, but where it likely originated. This is a fundamentally different approach from older tumor marker tests (like PSA or CA-125) that are single-protein, single-cancer.

Other Liquid Biopsy Developments

Johns Hopkins (April 2025): Developed an AI liquid biopsy specifically for brain cancer (glioblastoma) from a simple blood draw, identifying tumor DNA fragments alongside immune cell DNA patterns. GBM is currently only detectable via MRI or brain biopsy.
DELFI model: cfDNA fragmentation analysis achieved 94% sensitivity and 80% specificity for lung cancer
LunaCAM: Refines CT-based lung cancer screening using cfDNA methylation layers

Our Assessment

At ~$80/month annualized, the Galleri test is probably the single highest-leverage cancer intervention you can buy. It doesn't prevent cancer. It detects it before it kills you. The shift from Stage IV detection to Stage I detection changes survival odds from single digits to 90%+ for many cancer types. The trial data is strong and from large, well-designed studies. The main barrier is cost and insurance coverage, both of which will likely improve as FDA approval progresses.

Sources

GRAIL PATHFINDER 2 results: ESMO 2025
NHS-Galleri Trial: grail.com press release February 2026
Johns Hopkins AI liquid biopsy: Hopkins Medicine, April 2025
PMC12223554: AACR 2025 comprehensive liquid biopsy review